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Abstract
Both point mutations and deletions of the MYT1L gene as well as microdeletions of
chromosome band 2p25.3 including MYT1L are associated with intellectual disability,
obesity, and behavioral problems. Thus, MYT1L is assumed to be the—at least mainly—
causative gene in the 2p25.3 deletion syndrome. Here, we present comprehensive
descriptions of nine novel individuals bearing MYT1L mutations; most of them single
nucleotide variants (SNVs). This increases the number of known individuals with causa-
tive deletions or SNVs ofMYT1L to 51. Since eight of the nine novel patients bear muta-
tions affecting MYT1L only, the total number of such individuals now nearly equals the
number of individuals with larger microdeletions affecting additional genes, allowing for
a comprehensive phenotypic comparison of these two patient groups. For example,
55% of the individuals with mutations affecting MYT1L only were overweight or obese
as compared to 86% of the individuals with larger microdeletions. A similar trend was
Isabelle C. Windheuser, Jessica Becker, and Kirsten Cremer contributed equally as first authors.
Roberto Colombo, Maja Hempel, and Hartmut Engels contributed equally as senior authors.
Received: 7 November 2019 Revised: 16 January 2020 Accepted: 28 January 2020
DOI: 10.1002/ajmg.a.61515
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc.
Am J Med Genet. 2020;1–11. wileyonlinelibrary.com/journal/ajmga 1
observed regarding short stature with 5 versus 35%, respectively. However, these differ-
ences were nominally significant only after correction for multiple testing, further
supporting the hypothesis that MYT1L haploinsufficiency is central to the 2p25.3 dele-
tion phenotype. Most importantly, the large number of individuals with MYT1L muta-
tions presented and reviewed here allowed for the delineation of a more comprehensive
clinical picture. Seizures, postnatal short stature, macrocephaly, and microcephaly could
be shown to be over-represented among individuals withMYT1Lmutations.
K E YWORD S
chromosomal microarray, intellectual disability, microdeletion 2p25.3,MYT1L, obesity, whole
exome sequencing
1 | INTRODUCTION
Heterozygous mutations in the myelin transcription factor-1 like
(MYT1L) gene are responsible for autosomal dominant mental
retardation-39 (MRD39, OMIM # 616521) which is characterized by
intellectual disability/developmental delay (ID/DD), diverse behavioral
manifestations including aggressive behavior and autistic features as
well as obesity or overweight. The facial phenotype does not seem to
be recognizable. Up to now, the most frequent type of variation
described for MYT1L are microdeletions which often include addi-
tional genes while considerably less individuals with single nucleotide
variants (SNVs) of MYT1L have been reported (Al Tuwaijri & Alfadhel,
2019; Becker, Jaggard, & Horrocks, 2010; Blanchet et al., 2017;
Bonaglia, Giorda, & Zanini, 2014; de Ligt et al., 2012; De Rocker et al.,
2015; Doco-Fenzy et al., 2014; Loid et al., 2018; Mayo et al., 2015;
Rio et al., 2013; Stevens et al., 2011; Wang et al., 2016). MYT1L has
been shown to be the main causative gene in such submicroscopic
deletions of chromosome band 2p25.3 (Blanchet et al., 2017; De
Rocker et al., 2015). A previous comparison of individuals with MYT1L
deletion versus MYT1L SNVs identified no significant difference
regarding the main clinical features (Blanchet et al., 2017).
Here, we present a comprehensive clinical characterization of nine
novel individuals from eight families bearing MYT1L mutations. Six of
the novel variants are SNVs or small indels and two are microdeletions.
To our knowledge, this increases the number of known individuals with
MYT1L mutations to 51. Based on this large number, certain features
such as postnatal short stature could be identified as significantly over-
represented among individuals with MYT1L mutations. Additionally, an
even distribution between individuals carrying mutations affecting
MYT1L only (SNVs, indels, and small microdeletions) and individuals
with larger microdeletions affecting additional genes is achieved. A
comparison of the proportions of individuals with certain clinical fea-
tures between these two groups was performed.
2 | MATERIALS AND METHODS
All individuals presented here were originally ascertained during
genetic counseling or genetic diagnostics with ID/DD as the most
frequent and prominent reason. Additional reasons for ascertainment
were behavioral issues (two individuals) and, for example, microceph-
aly, seizures or obesity (one individual each).
Individuals 1 and 2 were identified in a study to elucidate new
candidate ID genes by trio whole exome sequencing (WES) in a cohort
of 311 individuals with unexplained ID and their unaffected parents.
The inclusion criteria were ID/DD with or without additional features
(e.g., craniofacial dysmorphism, organ malformation, etc.) which could
not be attributed to a clinically recognizable syndrome by an experi-
enced clinical geneticist. Clinically relevant chromosomal aberrations
were excluded by chromosome microarray analysis (CMA). Written
informed consent to the study and to the publication of the clinical
photographs was obtained from the legal representatives. All investi-
gations were performed in accordance with the protocols of the Dec-
laration of Helsinki and were approved by the local institutional
review board (Ethics Committee of the Medical Faculty of the Univer-
sity of Bonn, approvals 131/08 and 024/12). WES was performed as
published previously (Schafgen et al., 2016).
Trio WES with DNA samples of individuals 3, 4, 5, and 8 as well
as of their healthy parents was performed after written informed con-
sent as described previously (Hempel et al., 2015).
WES of individuals 6a (son) and 6b (father) as well as their unaf-
fected mother/wife and sister/daughter was performed after written
consent as published previously (Youssefian et al., 2019). Genomic
variants were filtered and prioritized according to the following
criteria: heterozygous presence in the affected father and son and
absence in the unaffected mother and daughter; gene reported to be
involved in neurologic or mental disorders; frequency in publicly avail-
able variant databases <0.01%; and in silico predicted pathogenic
effect of the variant.
Sanger sequencing was performed by standard methods to con-
firm all MYT1L sequence variants and their de novo status or in the
case of individuals 6a and b its parental origin. Primer sequences are
available upon request. The Combined Annotation Dependent Deple-
tion tool (CADD, version GRCh37-v1.4, [Kircher et al., 2014]) was used
to determine the potential pathogenicity of the identified variants.
After informed consent, CMA of individual 7 (8×60K ISCA v2.0
oligonucleotide array [BlueGnome], backbone resolution ~0.25 Mb)
identified a 0.43 Mb deletion at chromosome band 2p25.3 which was
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WINDHEUSER ET AL. 3
confirmed by FISH using a BAC probe (RP11-90H11). The deletion
involves part of the MYT1L gene. Parental testing for the 2p25.3 dele-
tion was negative.
The reference sequence for MYT1L was NM_015025.2. The
nomenclature of sequence variants follows the recommendations of
HGVS (den Dunnen & Antonarakis, 2000). All data interpretation was
based on the GRCh37/hg19 human genome assembly.
Statistical significance of the differences in frequencies between
two patient groups with different mutation types was calculated for
five features (presence or absence of short stature, microcephaly and
overweight/obesity at last examination, presence or absence of sei-
zures, and autism spectrum disorder; ASD) using Fisher's exact test.
Bonferroni correction for multiple testing (n = 5) yielded a corrected
p value of p ≤ .01 as significance threshold. Age distribution at last
examination was compared between the “MYT1L only” patient group
(median/M = 13.07, SD = 11.43) and the group of patients with “larger
microdeletions” (M = 18.35, SD = 17.4). This comparison did not reveal
significant difference between the two groups (t test, p = .22). For one
patient, no information on age was provided in the original study
(Wang et al., 2016).
Overweight and obesity are defined according to the definitions of
the World Health Organization (de Onis & Lobstein, 2010) as follows:
Below 5 years: weight for height (kg/m) > +2SD/≤ +3SD: overweight, >
+3SD: obesity; Ages 5–19: BMI (kg/m2) > +1SD/≤ +2SD: overweight, >
+2SD: obesity; adults: BMI ≥ 25: overweight, BMI ≥ 30: obesity.
3 | CASE REPORTS AND RESULTS
3.1 | Case reports and genetic testing
Main findings and measurements at last examination are given in
Table 1.
Individual 1 is the third child of healthy, non-consanguineous Ger-
man parents. He was born by spontaneous vaginal delivery at 40 weeks
of gestation (gw 40) after an uncomplicated pregnancy and was small
for gestational age (weight: 2,380 g [−2.8 SD], length: 49 cm [−1.5 SD],
occipitofrontal circumference [OFC]: 33 cm [−2.0 SD]).
At the age of 1 year, muscular hypotonia and a delayed motor
development became obvious. He walked without support at the age
of 23 months. His expressive and receptive speech development was
delayed with first words at the age of 2.5 years. MFE (Munich func-
tional development diagnostics) at 4 years showed a developmental
level corresponding to 16–33 months, the Denver developmental
scale at an age of 6 years showed a level of 2–3 years. At the age of
12 years, he still used 2-to-3-word sentences with slurred and partly
incomprehensible pronunciation but his vocabulary comprised more
than 100 words. He still had significant fine and gross motor skill defi-
cits. No formal intelligence test was performed but his ID was esti-
mated to be in the moderate range.
He had mild behavioral abnormalities with aggressive outbursts
and fixation on certain persons and things. He needed stable rules in
his daily routines.
At the age of 2 years, a temporary mild hypothyroidism was diag-
nosed and he was treated with L-thyroxine for 2 years. Examinations
of his eyes, teeth, metabolic system, sleep-EEG, brain MRI, and audiol-
ogy gave normal results.
He attended a school for children with special needs. At the first
clinical genetic assessment at the age of 6 6/12 years, he presented
with microcephaly (OFC 49.5 cm, −2.2 SD) and clinodactyly (Figure 1).
Other measurements were normal (weight 20 kg, −1.0 SD; height
116 cm, −1.1 SD; BMI 14.9 kg/m2, −0.4 SD). His parents had normal
head circumferences (mother 55 cm, father 57.5 cm). In the last clini-
cal assessment at 12 5/12 years, all measurements were in the normal
range. He has red hair like his healthy sister, a thin upper lip and no
noticeable dysmorphic features (Figure 1).
Conventional karyotyping, FISH (whole chromosome paint 21),
microdeletion and microduplication screening (MLPA Kit P245, MRC
Holland) and chromosomal microarray (CMA) gave normal results. Trio
WES revealed a heterozygous de novo nonsense mutation in MYT1L
[NM_015025.2:c.1531G>T, p.(Gly511*); CADD 42].
Individual 2 is the second child of healthy, non-consanguineous
German parents. The pregnancy was uneventful except for gestational
diabetes and minor nicotine consumption. Individual 2 was born by
spontaneous vaginal delivery at gw 41 + 3 with a weight of 3,100 g
(−1.2 SD), a length of 52 cm (−0.2 SD) and an OFC of 34 cm (−1.0
SD). A nuchal loop was reported. The Apgar scores were 8/10/10.
Her motor development was delayed with crawling at 13 months,
sitting without support at 14 months and walking without support at
20 months. Truncal hypotonia was apparent since the age of 4 months
and poor fine and gross motor abilities were reported at the age of
8 years.
She spoke her first words at 8 months with a subsequent a delay
of expressive speech development (first two-word sentences at the
age of 2.5 years, 3-to-5-word sentences at her first clinical genetic
assessment at the age of 6 2/12 years). At this time, she presented
with tall stature and obesity (height: 132 cm,+2.5 SD; weight:
44.8 kg,+3.4 SD; BMI: 25.7 kg/m2,+3.2 SD) and a normal OFC (50 cm,
−1.0 SD). She was diagnosed with mild ID (SON-R at 4 years: IQ 59)
and showed behavioral problems with aggressive outbursts. The par-
ents reported frequent nose bleeding. Obesity started in her second
year of life, the parents reported a missing sense of satiation. At the
last clinical genetic assessment at the age of 8 years, she still pres-
ented with tall stature and obesity. She had minor, nonspecific dys-
morphic features including narrow palpebral fissures (possibly due
to her obesity), a short neck, tapering fingers, sandal gap, and short
distal phalanges of the toes with small nails (Figure 1). Her
skin shows striae distensae and regions of yellow-brown discolor-
ation at her neck along skin folds and in the armpits. She presented
with a rough voice, increased noise and pain sensitivity, insomnia
with nocturnal awakenings, and persisting muscular hypotonia.
According to the mother, she measured 170 cm (+3.7 SD) and
106 kg (+4.0 SD, BMI: 36.7 kg/m2, +3.3 SD) at the age of 10 9/12
years and menarche was at age 10 years. She attends a special
school for mentally handicapped children and cannot read nor write,
except her name.
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EEGs, brain MRI, audiometry, basic metabolic investigations, con-
ventional karyotyping, fragile X-syndrome and Prader Willi/Angel-
man-syndrome diagnostics, and CMA gave normal results. WES
revealed two heterozygous de novo splice site mutations in MYT1L
[NM_015025.2:c.2769-2A>G; CADD 33] and SETD1B [NM_015
048.1:c.3126+2C>T; CADD 10.9].
Individual 3, a 2 4/12 years old girl, is the second child of healthy
non-consanguineous parents. She was born after an uncomplicated
pregnancy by vaginal delivery at gw 40 + 1 with normal measure-
ments (weight: 3,530 g [+0.1 SD], length: 53 cm [+0.6 SD], OFC:
36 cm [+0.8 SD]). After a reportedly normal development in the first
months of life, a first generalized febrile seizure occurred at the age of
10 months, followed by recurrent febrile and nonfebrile seizures
which responded well to treatment with Valproate. Motor develop-
ment was delayed with rolling over at 9–10 months, unaided sitting at
15 months, and unsupported walking at 23 months with a gait that
continued to be unstable. She had a speech delay with ~20 words but
was raised bilingually. She seemed to tire very easily, while her muscle
tone was normal. She got agitated easily and had difficulties to con-
centrate. There were no organic malformations.
At the last examination at age 3 years and 5 months we saw an
agitated and restless girl with a clumsy gait who could speak only sin-
gle words and follow simple instructions. She was overweight,
macrocephalic, and slightly dysmorphic with low-set ears, synophrys
(familial), large palpebral fissures, and long eyelashes.
Extensive metabolic screening in blood, cerebrospinal fluid and urine
and cranial MRIs at the ages of 10 months, 20 months, and 2 4/12 years
gave normal results. Panel analysis of genes associated with epileptic
encephalopathy could not identify disease causing gene mutations.
Trio WES resulted in the discovery of a de novo missense variant
in MYT1L [NM_015025.2:c.1711G>A, p.(Gly571Arg), CADD 29.4].
Individual 4 is the first and only child of healthy unrelated parents
of German origin. She was born at term after uneventfully pregnancy
by vacuum extraction due to abnormal CTG. Birth measurements
were normal (weight 3,560 g [+0.2 SD], length 53 cm [+0.6 SD], OFC
35.5 cm [+0.5 SD]). Surgeries for bilateral inguinal hernia were per-
formed at ages of 7 and 8 weeks. A delay in motor development was
noted at the age of 6 months. Supported by physiotherapy, she
started to roll over, to sit unaided at and to walk without support at
the age of 9, 14, and 22 months, respectively. Her gait was unstable
and clumsy with frequent falling and poor balance; joint instability
was treated with leg braces. Gross and fine motor skills and slightly
delayed speech development improved over time. Her intelligence
was described as mildly impaired; formal testing has not been per-
formed. Abnormal behavior included auto-stimulation and hand ste-
reotypies with fluttering and washing movements. Over time,
aggression and auto-aggression became more prominent. She was shy
and reclusive with particularly reduced her interactions in noisy situa-
tions. The parents reported that she has difficulties falling asleep.
At the last examination at the age of 6 4/12 years, we saw a
friendly, open-minded girl with normal measurements. She spoke in
correct sentences and could follow simple tasks. The gait was clumsy
with inwardly rotated feet. Arms were always held in slight flexion at
the elbows, and hands in palmar flexion. Further examination revealed
joint hypermobility, axial muscular hypotonia and limb hypertonia,
increased tendon reflexes and poor balance. Minor dysmorphic fea-
tures included a long face, thick and horizontal eyebrows, small ver-
million, pointed chin, and simple ears.
F IGURE 1 Portrait and photographs of hands/feet of Individuals 1, 2, and 7. Facial appearance at the age of 6 (a) and 12 years (b), hands (f)
and feet (g) of Individual 1. Besides thin upper lip and fifth finger clinodactyly, no dysmorphisms were present. Facial appearance at the age of
6 (c) and 8 years (d), hands (h) and feet (i) of Individual 2. Note obesity and minor dysmorphic features including narrow palpebral fissures, a short
neck, tapering fingers, sandal gap, and short distal phalanges of the toes with small nails. Facial appearance (e) and hands (j) of Individual 7 at the
age of 9 years. Note mild facial dysmorphism with a long face, cupid bows, and upslanting palpebral fissures [Color figure can be viewed at
wileyonlinelibrary.com]
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Extended metabolic work up in blood, urine and CSF as well as
MRI of brain and spinal cord gave normal results. SSEP showed
slightly elevated latency in response to right n. tibialis stimulation.
CMA gave normal results.
Trio WES identified a de novo nonsense mutation in MYT1L
[NM_015025.2:c.223C>T, p.(Arg75*), CADD 35.0].
Individual 5 is the second child of healthy unrelated parents of
German origin. He was born at gw 38 by cesarean section due to
macrosomia. Birth measurements were: weight 4,230 g, +2.1 SD;
length 53 cm, +0.8 SD; OFC 37 cm, +1.5 SD. Perinatally, there was a
short episode of shallow breathing which was most likely due to an
aspiration. Delay in motor development, muscular hypotonia and poor
eye fixation were noted at the age of 7 months. At the age of
9 months, he experienced a fever-associated seizure treated success-
fully with levetiracetam.
At the last examination at the age of 19 months, we saw a
friendly boy with normal measurements. He showed a predominantly
truncal muscular hypotonia, strabismus, and mildly dysmorphic fea-
tures: a high and broad forehead, flat midface, deep-set eyes, a broad
and flat nasal bridge, small mouth with downturned corners, puffy
hands and feet, tapering fingers, rather short fifth fingers as well as
two small cafe-au-lait spots on the upper leg. Severe developmental
delay was apparent. The boy was able to stand on all fours and to sit,
but could not crawl, stand, nor walk. His fine motor skills were not
age-appropriate, but he had started sorting things or clapping them
together. His receptive and expressive speech development was
severely delayed: He made sounds but did not form words.
Extended metabolic work up in blood, urine and CSF as well as
cranial MRI and EEG (under treatment with levetiracetam) gave nor-
mal results.
Trio-WES resulted in the discovery of a de novo missense mutation
inMYT1L [NM_015025.2:c.1700G>C, p.(Arg567Pro), CADD 29.4].
Individual 6a was delivered at gw 37 + 2 by cesarean section after
a normal pregnancy. Birth length (47 cm, −1.5 SD) and head circum-
ference (32 cm, −1.7 SD) were within the lower range, and his weight
was 3,700 g (+1.2 SD). His development was delayed, especially con-
cerning speech and language. At 2 3/12 years he spoke <25 words
clearly and did not form sentences. Receptive language was impaired
with difficulties in playing with other children. Hearing impairment
was excluded. His motor development was mildly delayed (indepen-
dent sitting and walking at the age of 11 and 19 months, respectively).
He tended to display destructive behavior. Two febrile seizures
occurred at Ages 3 and 5 years. EEG showed abnormal peak waves
but was inconclusive. He had a history of hypotonia and feeding prob-
lems, systolic heart murmurs and mild gastroesophageal reflux. He
was diagnosed with attention deficit hyperactivity disorder and
attended a special school for children with language and communica-
tion disabilities. ASD was excluded by neuropsychological tests
(autism diagnostic interview—revised, autism-spectrum quotient, child
autism rating scale).
He was referred for clinical genetic assessment at the age of
27 years with normal measurements. Dysmorphic facial features
included a broad nasal bridge, wide nasal tip, short philtrum, large ears
with hyperplastic ear lobes, wide mouth, irregularly spaced teeth, rela-
tively small hands, and micro-orchidism. Hypotonia and hyperactivity
were observed. He had myopia and frequent otitis.
He had been institutionalized from 17 to 22 years of age, during
which occasional aggressive and self-injurious behaviors were
reported. After institutionalization, he lived at home with psychologi-
cal and social assistance and is unemployed. Neuropsychological tests
including Wechsler Adult Intelligence Scale/WAIS and Folstein test
revealed mild ID.
Conventional karyotyping of blood lymphocytes and fragile-X-
syndrome diagnostics gave normal results.
Individual 6b is the father of Individual 6a. According to his older
sister, he was delivered at term after an uncomplicated pregnancy
with a weight of ~3.2 kg (−1 SD) as only known birth measure. He suf-
fered from epilepsy until puberty.
At clinical genetic assessment at the age of 56 years, he was over-
weight and presented with mild dysmorphic craniofacial features: mild
strabismus, bulbous, rounded nasal tip, short and broad philtrum, wide
mouth, widely spaced teeth, thick lower lip, and an elongated neck.
Hypotonia and hyperactivity were observed. Aggressive outbursts in
stressful situations were reported. He is employed under supervision
as a warehouseman. Neuropsychological tests (see above) revealed
mild ID.
A heterozygous nonsense variant [NM_015025.2:c.3118A>T, p.
(Lys1040*), CADD 46.0] in MYT1L was identified both in the affected
father and son, but not in the unaffected mother and daughter.
Individual 7 is the first of three children of healthy unrelated par-
ents. She was born after uneventful pregnancy at gw 38 by normal
delivery. Her birth weight was 3,130 g (−0.1 SD) and her OFC at birth
was 33.5 cm (−0.6 SD). Her birth length is unknown. Her OFC at
6 weeks was 37 cm (−0.3 SD) and at 33 weeks it was 41.5 cm
(−2.4 SD).
She had normal gross motor developmental milestones, but her
fine motor skills were delayed. Her early speech development was
normal but her speech remained unclear and needed speech and lan-
guage therapy because of pronunciation difficulties. She was referred
to the pediatrician at the age of 4 ½ years because of concerns about
sensory behaviors, poor fine motor skills and issues regarding social
interactions. A cognitive assessment showed a verbal IQ of 75 and a
performance IQ of 67. She had autistic features with ritualistic behav-
ior and a very good memory for images. She was diagnosed with atyp-
ical autism. At the last examination at the age of 9 years,
measurements were normal. She had mild facial dysmorphism with a
long face, cupid bows, and upslanting palpebral fissures (Figure 1).
First signs of puberty were early, at the age of 9 years. She had
increased TSH with normal T4 and no indication for thyroid treatment
at that stage.
CMA identified a 0.43 Mb deletion on the short arm of chromo-
some 2 at p25.3 which was confirmed by FISH studies. It affects only
Exons 1 and 2 of the MYT1L gene. The deletion was shown to be
de novo.
Individual 8 is the fourth child of healthy non-consanguineous par-
ents and was born after an uneventful pregnancy at gw 37 + 6 GW by
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re-re-cesarean section with normal measurements (weight 3,120 g,
−0.4 SD; length 51 cm, 0 SD; OFC 34.5 cm, −0.2 SD). After an
unremarkable development in the first months of life, muscular hypo-
tonia, and delays in motor and speech development became obvious.
He started sitting with 1 year and walking at the age of 2.5 years. At
the age of 3 10/12 years he spoke only two words with an impaired
receptive language development. He hardly understood and followed
instructions and did not interact with other children. He had myopia
and strabismus, but did not accept wearing glasses.
The last examination at age 4 2/12 years showed a friendly but
reclusive boy with normal measurements and minor dysmorphic fea-
tures including thick eyebrows, low set ears, retrognathia, and very
soft skin. Extended blood analysis including metabolic analysis, cranial
MRT, EEG as well as chromosome analysis, and fragile X testing gave
normal results.
Trio WES identified a de novo heterozygous deletion of
~1.87 Mb (chr2:41,608-1,907,065) in 2p25.3 involving i.a. the genes
TPO and PXDN and the exons 14–25 of the MYT1L gene.
3.2 | Frequency comparison of findings in two
patient groups with different mutation types
To our knowledge, our study increases the number of published indi-
viduals with MYT1L deletions or SNVs to 51 (Al Tuwaijri & Alfadhel,
2019; Becker et al., 2010; Blanchet et al., 2017; Bonaglia et al., 2014;
De Rocker et al., 2015; Doco-Fenzy et al., 2014; Loid et al., 2018;
Mayo et al., 2015; Rio et al., 2013; Stevens et al., 2011; Wang et al.,
2016, DECIPHER patient 141). Thirty of these carry microdeletions,
3 of which affect only MYT1L and 27 of which affect additional genes.
Twenty-one individuals carry 20 different MYT1L SNVs (8 missense
and 12 potential loss of function mutations, i.e., nonsense [n = 6],
frameshift [n = 3], or splice mutations/exon skipping [n = 3]). Thus,
24 known individuals carry mutations affecting MYT1L only (i.e., 21
SNVs and three microdeletions) and 27 individuals carry larger micro-
deletions affecting additional genes. These numbers may allow for a
more comprehensive analysis of possible differences between the
clinical appearance of individuals with variants affecting only MYT1L
and that of individuals with microdeletions affecting additional genes.
These two groups of individuals will be referred to as “MYT1L only”
and “larger microdeletions” from now on. Significance of the fre-
quency differences between the two groups of individuals was calcu-
lated for five features (presence or absence at last examination of
short stature, microcephaly and overweight/obesity, presence or
absence of seizures, and ASD) using Fisher's exact test with a
Bonferroni-corrected p value of p ≤ .01 for multiple testing as signifi-
cance threshold. The findings are summarized in Table 2.
4 | DISCUSSION
In 2011, MYT1L was first proposed as the causative gene in 2p25.3
microdeletions and MYT1L haploinsufficiency as a cause for ID
(Stevens et al., 2011). Based on six individuals with differently sized
heterozygous de novo deletions and ID, obesity or overweight and/or
a square-shaped stature and five additional patients with overlapping
deletions from the DECIPHER database (https://decipher.sanger.ac.
uk), a smallest region of deletion overlap containing only MYT1L was
defined. In 2012, a de novo MYT1L splice site mutation was identified
as part of a larger study in a girl with ID, autistic features, normal
growth, and mild dysmorphism (de Ligt et al., 2012). After three publi-
cations on seven more individuals with microdeletions encompassing
MYT1L and global DD/ID, behavioral difficulties/hyperactivity and
overweight/obesity (Bonaglia et al., 2014; Doco-Fenzy et al., 2014;
Rio et al., 2013), de Rocker and colleagues published an extensive
study on 22 individuals bearing either chromosomal aberrations or
SNVs affecting MYT1L (De Rocker et al., 2015). Seventeen of these
22 individuals presented with obesity/overweight. Since four individ-
uals with MYT1L SNVs or microdeletions exclusively affecting MYT1L
were strikingly similar to the individuals with larger deletions, the
authors hypothesized that MYT1L is the causal gene for both
observed phenotypes. A further case report described an individual
with a de novo intragenic deletion of MYT1L and DD, microcephaly,
behavioral problems, and stereotypies, but without obesity at an age
of 4.5 years (Mayo et al., 2015). In 2017, Blanchet and colleagues
published the next larger series of novel patients with ID/DD,
reviewed the clinical phenotype and compared the clinical pictures of
SNV mutation carriers with that of microdeletion carriers (Blanchet
TABLE 2 Frequency comparison of findings between the two patient groups with different mutation types of MYT1L (“MYT1L only”
microdeletions and SNVs vs. “larger microdeletions”) for five features (presence or absence at last examination of short stature, microcephaly and
overweight/obesity, presence or absence of seizures, and ASD) using Fisher's exact test
Feature All individuals MYT1L only Larger microdeletions p value
Short stature at last examination 20.5% (9/44) 4.8% (1/21) 34.8% (8/23) .023
Microcephaly at last examination 11.4% (4/35) 17.6% (3/17) 5.6% (1/18) .338
Overweight/obesity at last examination 70.5% (31/44) 54.5% (12/22) 86.4% (19/22) .045
Seizures 76.2% (16/21) 66.7% (8/12) 88.9% (8/9) .338
ASD 43.2% (16/37) 66.7% (12/18) 21.1% (4/19) .008
Note: None of the five comparisons were below significance threshold/corrected p value of p ≤ .01 after Bonferroni correction for multiple testing.
Nominally significant p values are underlined.
Abbreviations: ASD, autism spectrum disorder; SNVs, single nucleotide variants.
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et al., 2017). In addition to one individual with a microdeletion, nine
individuals with de novo MYT1L SNVs were reported. The authors
then compared the proportions of individuals with the phenotypes ID,
gross motor delay, speech delay, autism, overweight/obesity, or
hyperphagia between 28 published and own individuals with deletions
affecting MYT1L and 11 published and own individuals with MYT1L
SNVs (Bonaglia et al., 2014; De Rocker et al., 2015; Doco-Fenzy et al.,
2014; Stevens et al., 2011). No significant differences between the
groups were found for any of the clinical features, supporting the
hypothesis that MYT1L haploinsufficiency is central to the 2p25.3
deletion phenotype. The overall proportion of individuals with over-
weight or obesity was 85%.
Here, we present nine novel individuals with MYT1L mutations.
The clinical findings of these novel individuals largely confirmed
the above-named clinical picture. All nine individuals had develop-
mental delay and (borderline) ID, six had muscular hypotonia, and
four had (febrile) seizures. Behavioral anomalies were seen in seven
of them and ASD in two. Only three of the nine individuals devel-
oped overweight/obesity postnatally. Thus, the frequency for over-
weight/obesity among these novel individuals is lower than
reported before with 33% as compared to, for example, the 85%
reported earlier (Blanchet et al., 2017). Severe congenital mal-
formations were absent and craniofacial dysmorphism was
generally mild.
Seven individuals carry MYT1L SNVs, two of which are familial
and identical (Individuals 6a and b), increasing the number of known
MYT1L SNV carriers by more than half. Individuals 1, 4, 6a, and 6b
carry nonsense variants in MYT1L and Individuals 3 and 5 missense
variants. A splice site mutation was detected in Individual 2 in addition
to a putative de novo splice site mutation of SETD1B. We are aware
of three published individuals with de novo missense or frameshift
variants of SETD1B and epilepsy, developmental delay, ID, autistic
behavior and craniofacial dysmorphic features, and in one case obe-
sity (Den et al., 2019; Hiraide et al., 2018). Thus, an additional effect
of the SETD1B variant in Individual 2 cannot completely be excluded
in spite of its low CADD score. However, several lines of evidence
point to an—if any—minor effect: First, all published individuals with
de novo SETD1B variants had severe myoclonic seizures which are
not present in Individual 2. Second, none of them had muscular hypo-
tonia which is present in Individual 2. Additionally, the three published
SETD1B variants affect the terminal SET domain of the protein while
the putative splice site mutation (rs749218728) in Individual 2 is
located much further upstream. According to earlier studies, this vari-
ant most likely causes nonsense mediated mRNA decay (NMD)
(Coban-Akdemir et al., 2018; Den et al., 2019) which in turn has been
postulated not to be damaging (Den et al., 2019). In two of the nine
individuals, de novo microdeletions affecting MYT1L were detected:
one of them affecting only two exons of MYT1L (Individual 7) and one
F IGURE 2 Genomic (a) and domain structure (b) of MYT1L with localizations of the mutations identified within this study (n = 9; upper panel)
and reported in previous studies (n = 15, lower panel). Those mutations that are localized in the coding region are also shown within the domain
structure (b). The respective color in the online version corresponds to the type of mutation: orange (nonsense), green (frameshift), and black
(missense) [Color figure can be viewed at wileyonlinelibrary.com]
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of them 12 exons of MYT1L and 12 additional RefSeq genes
(Individual 8).
To our knowledge, our study increases the number of published
individuals with MYT1L deletion or SNVs to 51. While a causal role of
MYT1L for the well-known clinical features ID/DD, ASD, behavioral
problems, and overweight/obesity is clearly confirmed, the large num-
ber of individuals presented and reviewed here allows for a more
comprehensive picture and the highlighting of additional, less frequent
clinical features associated with MYT1L mutations. Several clinical
findings which have only been mentioned in passing if at all in earlier
reviews are shown to be considerably over-represented among indi-
viduals with MYT1L mutations. Of the 21 individuals with information
on the presence or absence of seizures, 16 were affected (76.2%,
Table 2). Even if none of the individuals without explicit information
had had seizures, the resulting minimal frequency of 31.4% would still
be high. Other features concern the growth pattern of individuals with
MYT1L mutations besides their weight/BMI. For these features,
explicit information is available for most individuals. Thus, the obser-
vation seems quite robust that postnatal short stature, macrocephaly
and microcephaly with frequencies of 20.5, 13.5, and 8.1%, respec-
tively, are considerably over-represented among individuals with
MYT1L mutations.
Additionally, the sample size may allow for a more comprehen-
sive analysis of possible clinical differences between individuals
with deletion and SNV variation affecting only MYT1L and individ-
uals with larger microdeletions affecting additional genes. Twenty-
one individuals carry MYT1L SNVs and three carry microdeletions
which affect only MYT1L. In contrast to those 24 individuals with
genetic variation of MYT1L only (the “MYT1L only” group), 27 carry
microdeletions which affect additional genes (the “larger micro-
deletions” group). It should be kept in mind that these larger micro-
deletions are quite heterogeneous in their size, localization and
gene content. Consequently, the putative effects of larger deletions
may vary.
As a matter of course, we agree with the conclusion of earlier
publications that MYT1L haploinsufficiency is central to the etiology
of the clinical features of individuals with microdeletions of 2p25.3
affecting MYT1L. One important example is overweight or obesity
which affected all reported individuals with microdeletions affecting
MYT1L in the first review, (Stevens et al., 2011). De Rocker et al.
found overweight/obesity of childhood onset in 71% of their deletion
patients and both of their SNV patients (De Rocker et al., 2015) and
Blanchet and colleagues in 85% of their novel and reviewed patients
(Blanchet et al., 2017). However, only three out of the nine novel indi-
viduals presented here were affected. Taken together with all previ-
ously published individuals, this results in an overall proportion of
individuals with overweight/obesity of 70.5% (31/44) with over-
weight in 29.5%, and obesity in 40.9%. As stated above, we wanted
to explore if the numbers of both “MYT1L only” individuals and “larger
microdeletion” individuals are now large enough to reach statistical
significance for potential differences between these two patient
groups. While 54.5% (12/22) of the “MYT1L only” individuals are
overweight/obese, the proportion among individuals with “larger
microdeletions” is 86.4% (19/22). This difference is nominally signifi-
cant only (p = .045) and does not reach significance after correction
for multiple testing.
Regarding the less frequently discussed features, postnatal micro-
cephaly yielded no frequency difference between the two groups
(MYT1L only: 3/17, larger microdeletions 1/18, p = .338). However,
especially postnatal short stature may merit closer attention. It was
reported in three out of six individuals by Stevens and colleagues but
was not addressed in subsequent studies. Of all 44 individuals with
postnatal height measurements reported now, nine (20.5%) had post-
natal short stature. Interestingly, only one out of 21 (4.8%) “MYT1L
F IGURE 3 Model of the second (blue) and third (green) zinc fingers of MYT1L bound to DNA. The gray spheres represent the zinc ions, with
the CCHC zinc ligands shown in purple. All reported missense variants (depicted in orange) identified in eight individuals are localized in the zinc
finger domains. The missense variants of Individual 5 and Individual #2 from Blanchet et al. affect the same amino acid (position 567). The figure
shows the missense variant of Individual 5 (p.R567P). The image was created using Pymol Version 2.3 (https://www.pymol.org/) [Color figure can
be viewed at wileyonlinelibrary.com]
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only” individuals, but eight out of 23 (34.8%) for the “larger micro-
deletions” group had short stature (p = .023). Again, this difference is
only nominally significant. This clearly shows that the differences
between the two groups are very small if they exist at all, unde-
rscoring the importance of MYT1L haploinsufficiency for the etiology
of the clinical features of individuals with microdeletions of 2p25.3
affecting MYT1L. However, the Bonferroni correction used here is
quite conservative as it is generally used for independent tests while
two of the tests included in the correction here (height and
BMI/weight) are not entirely independent. Additionally, insufficient
power of the sample analyzed here cannot be excluded. Thus, our
data may constitute a—however to date definitely insignificant—hint
at a higher overall incidence of postnatal short stature and over-
weight/obesity in the patient group with additional deleted genes.
Additional studies with even larger samples of individuals with differ-
entMYT1L variation are necessary.
Seizures were described in 76.2% of all individuals with no differ-
ence between groups (MYT1L only: 8/12, larger microdeletions 8/9,
p = .338). While the overall proportion of different behavioral anoma-
lies is very similar for both groups (95.8 vs. 100%), there seems to be
a difference for the presence of ASD. This proportion seems to be sig-
nificantly higher in the “MYT1L only” group with 66.7% (12/18) than
in the “larger microdeletions” group with 21.1% (4/19, p = .008). How-
ever, this should be interpreted with utmost caution since ASD is
much more prone to ascertainment differences than features which
are determined more easily and more comprehensively such as body
measurements. The overall proportion of individuals with reported
ASD is 43.2% and thus slightly higher than the one reported by Bla-
nchet and colleagues.
We were also interested in the localization of the many different
mutations within MYT1L (Figure 2). The nonsense and frameshift vari-
ants do not seem to show any clustering or preferential localizations.
Even the rather N-terminal nonsense mutations of Individuals 6a and
6b do not seem to be associated with a distinguishable clinical picture.
A possible explanation for this may be mRNA NMD as opposed to
truncation which would more likely give rise to distinguishable clinical
pictures caused by proteins of different lengths and domain contents.
However, this hypothesis could not be analyzed for lack of suitable
patient material. Equally, we could not find evidence for preferential
deletions of certain regions of the gene neither for deletions within
the gene nor for deletions affecting the N- or the C-terminus of the
gene (Figure 2) or for different deletion localizations being associated
with different clinical pictures. Interestingly, all seven known missense
variants (identified in eight individuals) are localized in the second and
third zinc finger domains and therefore are likely to interfere with
DNA binding (Figures 2 and 3).
In summary, we present nine novel individuals from eight families
with different types of mutations affecting MYT1L, seven of them
with SNVs affecting MYT1L and two of them with microdeletions
affecting either MYT1L only or MYT1L and additional genes. Seven of
the individuals carry de novo mutations and one SNV is shared by an
affected son and his affected father in whose case the origin of the
mutation could not be analyzed.
Our study gives the most comprehensive picture of the clinical
appearance of individuals with MYT1L mutations so far. The typical
clinical picture of ID/DD together with frequent overweight or obe-
sity is confirmed. Overweight/obesity is present in 70.5% of individ-
uals and thus slightly less frequent than reported before. Altogether,
the number of affected individuals now is 51, allowing for the most
comprehensive clinical picture yet. Thus, several clinical findings such
as seizures, short stature, macrocephaly, and microcephaly which have
not been in the focus so far could be shown to be clearly over-
represented among individuals withMYT1L mutations.
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